Literature DB >> 7315851

Bromocriptine therapy for "nonfunctioning" pituitary tumors.

D G Johnston, K Hall, A McGregor, W M Ross, P Kendall-Taylor, R Hall.   

Abstract

Bromocriptine therapy may cause regression of prolactinomas, but its effect on nonsecretory pituitary tumors is uncertain. Conventional treatment for such "functionless" tumors is surgery and/or radiotherapy, but recurrences pose a therapeutic dilemma. We describe a patient with such a tumor treated by surgery and radiotherapy who presented with recurrent disease 14 days later. On treatment with bromocriptine, 20 mg daily for 25 months, the intrasellar tumor recurrence had diminished in size and a suprasellar extension had almost disappeared. Bromocriptine therapy may therefore benefit some patients with nonsecretory pituitary tumors considered unsuitable for surgery or radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7315851     DOI: 10.1016/0002-9343(81)90342-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  D J Kwekkeboom; W W de Herder; E P Krenning
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas.

Authors:  Erica C Garcia; Luciana A Naves; Arthur O Silva; Lucas F de Castro; Luiz A Casulari; Monalisa F Azevedo
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

Review 3.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

4.  Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology.

Authors:  M Nissim; B Ambrosi; V Bernasconi; G Giannattasio; M A Giovanelli; M Bassetti; U Vaccari; P Moriondo; A Spada; P Travaglini; G Faglia
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

Review 5.  Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.

Authors:  C Capatina; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

6.  Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas.

Authors:  G Verde; G Oppizzi; P G Chiodini; D Dallabonzana; G Luccarelli; A Liuzzi
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.